- Home
- NVO vs AZN Comparison
NVO vs AZN Comparison
Compare NVO & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVO | AZN |
|---|---|---|
| Founded | 1923 | 1992 |
| Country | Denmark | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.6B | 285.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NVO | AZN |
|---|---|---|
| Price | $39.68 | $195.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $51.00 | N/A |
| AVG Volume (30 Days) | ★ 19.9M | 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.19% | 1.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.13 |
| Revenue Next Year | $4.39 | $6.21 |
| P/E Ratio | ★ $13.60 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.85 | $61.24 |
| 52 Week High | $82.23 | $212.71 |
Technical Indicators
Market Signals| Indicator | NVO | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 61.95 |
| Support Level | N/A | $89.28 |
| Resistance Level | $50.30 | $211.32 |
| Average True Range (ATR) | 0.89 | 3.38 |
| MACD | 0.03 | -5.22 |
| Stochastic Oscillator | 28.36 | 20.00 |
Price Performance
Historical ComparisonAbout NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.